source
- Vertex kidney disease drug faces infection risk scrutiny ahead of FDA decisionVertex's kidney disease therapy is expected to receive FDA approval, with the agency's decision scheduled for Nov 30. A previously undisclosed pause rule has drawn attention, raising concerns abou…
- Flagship Pioneering merges three biotech startups to launch AI-driven drugmaker EtceleraFlagship Pioneering announced the creation of Etcelera Therapeutics by merging three of its portfolio companies - Etiome, Cellarity and Empress Therapeutics. The new venture will combine artificia…